Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 4

EPIX Pharmaceu Form 4	ticals, Inc.									
May 21, 2008										
FORM 4									PPROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Estimated burden hoi response	urs per	
(Print or Type Respo	nses)									
1. Name and Address of Reporting Person <u>*</u> Gilman Michael			2. Issuer Name and Ticker or Trading Symbol EPIX Pharmaceuticals, Inc. [EPIX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle)			3. Date of Earliest Transaction				(Check an applicable)			
C/O EPIX PHARMACEUTICALS, INC., 4 MAGUIRE ROAD			(Month/Day/Year) 05/19/2008			X_ Director 10% Owner Officer (give title Other (specify below) below)				
			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
LEXINGTON, N	MA 02421						Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative S	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	ansaction Date hth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8) Code V		A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report or	n a separate line	for each cl	ass of sec	urities bene	ficially own	ed directly	or indirectly.			
					Persor inform require	ns who res ation cont ed to resp /s a curre	spond to the colle lained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)		str. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
			Cod	de V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 1.9	05/19/2008	А	X	10,000		<u>(1)</u>	05/19/2018	Common Stock	10,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Gilman Michael C/O EPIX PHARMACEUTICALS, INC. 4 MAGUIRE ROAD LEXINGTON, MA 02421	Х						
Signatures							
/s/ Kim Cobleigh Drapkin, Attorney-in-Fact	05	/21/2008					
**Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests in full on the earlier of (i) the first anniversary date of the grant or (ii) the date of EPIX Pharmaceuticals, Inc.'s next annual meeting, in each case provided that the optionee is still a director of EPIX Pharmaceuticals, Inc. on such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.